SCHEMBL3697392

SCHEMBL3697392

Cc1ccnc(Nc2ccc(C#N)cc2)n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 2/20 0.58
SCN5A Q14524 1/20 0.58
SCN9A Q15858 1/20 0.58
MEN1 O00255 1/20 0.58
KMT2A Q03164 1/20 0.58
CYP2C19 P33261 4/20 0.54
CYP2C9 P11712 3/20 0.54
ABCG2 Q9UNQ0 3/20 0.53
CYP3A4 P08684 2/20 0.53
CYP1A2 P05177 1/20 0.53
CYP2D6 P10635 1/20 0.53
SYK P43405 2/20 0.52
IKBKB O14920 2/20 0.52
CDK4 P11802 2/20 0.49
CDK2 P24941 2/20 0.49
GSK3B P49841 2/20 0.49
DYRK1A Q13627 1/20 0.49
JAK2 O60674 1/20 0.49
KDM4E B2RXH2 1/20 0.46
EPHB4 P54760 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10225814 0.81 SCN9A (0.58) KCNH2SCN5ASCN9AMEN1KMT2A
SCHEMBL10177401 0.81 SCN9A (0.84) KCNH2SCN5ASCN9AMEN1KMT2A
SCHEMBL4486162 0.81 KCNH2 (0.58) KCNH2SCN5ASCN9AMEN1KMT2A
SCHEMBL867999 0.81 KCNH2 (0.58) KCNH2SCN5ASCN9AMEN1KMT2A
SCHEMBL13713315 0.81 KCNH2 (0.58) KCNH2SCN5ASCN9AMEN1KMT2A
SCHEMBL13729887 0.80 MEN1 (0.64) KCNH2SCN5ASCN9AMEN1KMT2A
SCHEMBL1741981 0.79 KCNH2 (0.55) KCNH2SCN5ASCN9AMEN1KMT2A
SCHEMBL2864184 0.78 CYP2C19 (0.56) KCNH2SCN5ASCN9AMEN1KMT2A
SCHEMBL22628094 0.78 NPC1 (0.45) KCNH2SCN5ASCN9AMEN1KMT2A
SCHEMBL19575358 0.78 AURKA (0.57) KCNH2SCN5ASCN9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9192577-B2 Pharmaceutical compositions comprising a basic drug compound, a surfactant, and a physiologically tolerable water soluble acid JANSSEN PHARMACEUTICA NV (BE) 2015-11-24 US disclosed
US-8809343-B2 Pyrimidine derivative, preparation method and use thereof FUDAN UNIVERSITY (CN) 2014-08-19 US disclosed
US-20120122902-A1 PYRIMIDINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF FUDAN UNIVERSITY (CN) 2012-05-17 US disclosed
US-8101752-B2 Process for preparing 4-[(1,6-dihydro-6-oxo-2-pyrimidinyl)amino]benzonitrile TIBOTEC PHARMACEUTICALS LTD. (IE) 2012-01-24 US disclosed
US-8080551-B2 HIV inhibiting pyrimidines derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2011-12-20 US disclosed
US-20080171878-A1 Process for Preparing 4-[(1,6-Dihydro-6-Oxo-2-Pyrimidinyl)Amino]Benzonitrile JANSSEN SCIENCES IRELAND UC (IE) 2008-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171878-A1 Process for Preparing 4-[(1,6-Dihydro-6-Oxo-2-Pyrimidinyl)Amino]Benzonitrile ME1, ALKBH1, DPYD KCNH2 985/4885SCN5A 2879/4885SCN9A 2721/4885
US-20120122902-A1 PYRIMIDINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF DPYD, TYMP, TYMS KCNH2 2717/4885SCN5A 3258/4885SCN9A 4236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.